삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 박영석 교수

진료분야
대장암
진료일정 09 月
날짜
금
01
토
02
일
03
월
04
화
05
수
06
목
07
금
08
토
09
일
10
월
11
화
12
수
13
목
14
금
15
토
16
일
17
월
18
화
19
수
20
목
21
금
22
토
23
일
24
월
25
화
26
수
27
목
28
금
29
토
30
오전
오후
진료일정 10 月
날짜
일
01
월
02
화
03
수
04
목
05
금
06
토
07
일
08
월
09
화
10
수
11
목
12
금
13
토
14
일
15
월
16
화
17
수
18
목
19
금
20
토
21
일
22
월
23
화
24
수
25
목
26
금
27
토
28
일
29
월
30
화
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
1999.02 고려대학교 의과대학원 박사학위 취득
1992.02 서울대학교 의과대학원 석사학위 취득
1986.02 서울대학교 의과대학 졸업

경력

경력
2007.03 ~현재 삼성서울병원 혈액종양내과 교수
2014.03 ~ 2019.03 삼성서울병원 임상의학연구소장
2015.03 ~ 2017.03 삼성서울병원 혈액종양내과분과장
2003.04 ~ 2007.02 삼성서울병원 혈액종양내과 부교수
2000.12 ~ 2003.03 국립암센터 부속병원 임상시험센터 센터장
1991.03 ~ 2000.11 한림대학교 의과대학 부교수
1996.09 ~ 1997.11 미국 피츠버그 대학,<br> National Surgical Adjuvant Breast and Bowel Project, Consultant
1993.06 ~ 1993.09 미국 Fred Hutchinson Cancer Research Center, clinical fellow
1990.03 ~ 1991.02 서울대학병원 혈액종양내과 전임의
1987.03 ~ 1990.02 서울대학병원 내과 전공의
1986.03 ~ 1987.02 서울대학병원 인턴

학회활동

학회활동
대한 내과학회
대한 암학회
대한 종양내과학회
대한항암요법연구회
미국임상암학회, American Society of Clinical Oncology
논문
  • MOL IMAGING BIOL 2023 10.1007/s11307-023-01832-7 A Machine Learning Approach Using [F-18]FDG PET-Based Radiomics for Prediction of Tumor Grade and Prognosis in Pancreatic Neuroendocrine Tumor Park, YJ; Park, YS; Kim, ST; Hyun, SH
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.01740 Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study Park, JH; Hong, JY; Shen, JJ; Han, K; Park, JO; Park, YS; Lim, HY
    View PubMed
  • THER ADV GASTROENTER 2023 10.1177/17562848231170484 The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation Jeong, SY; Hong, JY; Park, JO; Park, YS; Lim, HY; Jang, JY; Jeon, Y; Kim, ST
    View PubMed
  • CANCER COMMUN 2023 10.1002/cac2.12406 Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study Iwasa, S; Wang, ZX; Muro, K; Morita, S; Park, YS; Zhang, DS; Yamada, Y; Sakamoto, J; Kim, TW
    View PubMed
  • J CANCER RES CLIN 2023 10.1007/s00432-022-03946-x Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen Beom, SH; Kim, JG; Baik, SH; Shin, SH; Park, I; Park, YS; Lee, MA; Lee, S; Jeon, SY; Han, SW; Kang, MH; Oh, J; Kim, JS; Kim, JY; Ahn, MS; Zang, DY; Bae, BN; Jo, HJ; Kim, HK; Kim, JH; Yoon, JA; Kim, DH
    View PubMed
  • ASIA-PAC J CLIN ONCO 2023 10.1111/ajco.13920 Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study Yang, TS; Chen, HH; Bo-Wen, L; Kim, TW; Kim, JG; Ahn, JB; Lee, MA; Lin, J; Ho, GF; Anh, L; Temraz, S; Burge, M; Chua, C; Huang, J; Park, YS
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1527 A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer Jo, H; Kim, ST; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Il Yu, J; Park, HC; Choi, DH; Park, Y; Cho, YB; Huh, JW; Yun, SH; Kim, HC; Lee, WY; Kang, WK
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.22.00145 Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study Park, JH; Hong, JY; Han, K; Park, YS; Park, JO
    View PubMed
  • PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.02962 Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 Kim, ST; Kim, SY; Lee, J; Yun, SH; Kim, HC; Lee, WY; Kim, TW; Hong, YS; Lim, SB; Baek, JY; Oh, JH; Ahn, JB; Shin, SJ; Han, SW; Kim, SG; Kang, SY; Sym, SJ; Zang, DY; Kim, YH; Choi, IS; Kang, JH; Kim, MJ; Park, YS
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1194 Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study Kwon, J; Lee, JH; Lee, YH; Lee, J; Ahn, JH; Kim, SH; Kim, SH; Il Kim, T; Yun, KH; Park, YS; Kim, JE; Lee, KS; Choi, JK; Kim, HS
    View PubMed
  • J CANCER RES CLIN 2022 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • J ONCOL 2022 10.1155/2022/9714570 Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2021.12.027 Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study Park, JH; Han, K; Hong, JY; Park, YS; Park, JO
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.834104 HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer Kim, H; Kim, R; Kim, HR; Jo, H; Kim, H; Ha, SY; Park, JO; Park, YS; Kim, ST
    View PubMed
  • GASTROENTEROLOGY 2022 10.1053/j.gastro.2021.09.070 Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study Park, JH; Han, K; Hong, JY; Park, YS; Hur, KY; Kang, G; Park, JO
    View PubMed
  • INVEST NEW DRUG 2021 10.1007/s10637-021-01078-6 A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors Keam, B; Ock, CY; Kim, TM; Oh, D; Kang, WK; Park, YH; Lee, J; Lee, JH; Ahn, YH; Kim, HJ; Chang, SK; Park, J; Choi, JY; Song, YJ; Park, YS
    View PubMed
  • TECHNOL CANCER RES T 2021 10.1177/15330338211062324 Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer Kim, H; Kim, H; Kim, R; Jo, H; Kim, HR; Hong, J; Park, JO; Park, YS; Kim, ST
    View PubMed
  • CANCER SCI 2021 10.1111/cas.15092 Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer Iwasa, S; Muro, K; Morita, S; Park, YS; Nakamura, M; Kotaka, M; Nishina, T; Matsuoka, H; Ahn, JB; Lee, KW; Hong, YS; Han, SW; Cho, SH; Zhang, DS; Fang, WJ; Bai, L; Yuan, XL; Yuan, Y; Yamada, Y; Sakamoto, J; Kim, TW
    View PubMed
  • METABOLISM 2021 10.1016/j.metabol.2021.154848 Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study Park, JH; Hong, JY; Park, YS; Kang, G; Han, K; Park, JO
    View PubMed
  • INVEST NEW DRUG 2021 10.1007/s10637-021-01110-9 A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer Jeong, H; Hong, YS; Kim, JE; Lim, HS; Ahn, JB; Shin, SJ; Park, YS; Kim, ST; Han, SW; Kim, TY; Kim, TW
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.06.052 Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population- based cohort study Park, JH; Hong, JY; Park, YS; Kang, GS; Han, K; Park, JO
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/17588359211038478 Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer Hong, JY; Cho, HJ; Kim, ST; Park, YS; Shin, SH; Han, IW; Lee, JY; Heo, JS; Park, JO
    View PubMed
  • INVEST NEW DRUG 2021 10.1007/s10637-021-01110-9 A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer Jeong1, H; Hong, YS; Kim, JE; Lim, HS; Ahn, JB; Shin, SJ; Park, YS; Kim, ST; Han, SW; Kim, TY; Kim, TW
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ONCOLOGIST 2021 10.1002/onco.13735 Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT) Kim1, SY; Lee, JS; Kang, J; Morita, S; Park, YS; Sakamoto, J; Muro, K; Xu, RH; Kim, TW
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • IN VIVO 2021 10.21873/invivo.12284 ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy Kim1, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO
    View PubMed
  • J CANCER 2021 10.7150/jca.49176 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2020 10.1016/j.clcc.2020.03.004 A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases Chun1, YJ; Kim, SG; Lee, KW; Cho, SH; Kim, TW; Baek, JY; Park, YS; Hong, S; Chu, CW; Beom, SH; Jung, M; Shin, SJ; Ahn, JB
    View PubMed
  • EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855 Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920926796 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
    View PubMed
  • Transl Cancer Res 2020 10.21037/tcr-19-1876 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.261 Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer Yoo1, GS; Park, HC; Yu, JI; Choi, DH; Cho, WK; Park, YS; Park, JO; Lim, HY; Kang, WK; Lee, WY; Kim, HC; Yun, SH; Cho, YB; Park, YA; Song, KD; Kim, SH; Ha, SY
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00706-0 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-019-00691-z Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • J ONCOL 2020 10.1155/2020/4659062 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.01327 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J
    View PubMed
  • J CLIN ONCOL 2019 10.1200/JCO.19.00016 Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial Hong1, YS; Kim, SY; Lee, JS; Nam, BH; Kim, KP; Kim, JE; Park, YS; Park, JO; Baek, JY; Kim, TY; Lee, KW; Ahn, JB; Lim, SB; Yu, CS; Kim, JC; Yun, SH; Kim, JH; Park, JH; Park, HC; Jung, KH; Kim, TW
    View PubMed
  • J Cancer 2019 10.7150/jca.37610 Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY
    View PubMed
  • J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-51981-5 Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • Transl Cancer Res 2019 10.21037/tcr.2019.09.27 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • Am J Transl Res 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.379 A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.401 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdz058 Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J
    View PubMed
  • PLoS One 2019 10.1371/journal.pone.0215080 Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J
    View PubMed
  • ANN SURG 2019 10.1097/SLA.0000000000002582 Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer Jang1, JH; Kim, HC; Huh, JW; Park, YA; Cho, YB; Yun, SH; Lee, WY; Yu, JI; Park, HC; Park, YS; Park, JO
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • SURGERY 2019 10.1016/j.surg.2018.08.026 Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy Huh1, JW; Kim, HC; Kim, SH; Park, YA; Cho, YB; Yun, SH; Lee, WY; Park, HC; Choi, DH; Park, JO; Park, YS; Chun, HK
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S182259 Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study Yao1, JC; Oh, DY; Qian, JM; Park, YS; Herbst, F; Ridolfi, A; Izquierdo, M; Ito, T; Jia, LQ; Komoto, I; Sriuranpong, V; Shimada, Y
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S187621 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2016.348 The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-O4 study Byun1, JH; Ahn, JB; Kim, SY; Kang, JH; Zang, DY; Kang, SY; Kang, MJ; Shim, BY; Baek, SK; Kim, BS; Lee, KH; Lee, SI; Cho, SH; Sohn, BS; Kim, S; Hwang, IG; Nam, EM; Seo, BG; Oh, SC; Lee, MA; Lee, SC; Hong, JH; Park, YS
    View PubMed
  • PATHOL RES PRACT 2019 10.1016/j.prp.2018.10.024 The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma Cho1, J; Kim, KM; Kim, HC; Lee, WY; Kang, WK; Park, YS; Ha, SY
    View PubMed
  • J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH
    View PubMed
  • RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-018-4995-0 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO
    View PubMed
  • J GASTROINTEST SURG 2018 10.1007/s11605-018-3815-9 Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer Huh1, JW; Yun, SH; Kim, SH; Park, YA; Cho, YB; Kim, HC; Lee, WY; Park, HC; Choi, DH; Park, JO; Park, YS; Chun, HK
    View PubMed
  • NAT MED 2018 10.1038/s41591-018-0101-z Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy241 Nintedanib for the treatment of patients win refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized placebo-controlled study Van Cutsem1, E; Yoshino, T; Lenz, HJ; Lonardi, S; Falcone, A; Limon, ML; Saunders, M; Sobrero, A; Park, YS; Ferreiro, R; Hong, YS; Tomasek, J; Taniguchi, H; Ciardiello, F; Stoehr, J; Oum'Hamed, Z; Vlassak, S; Studeny, M; Argiles, G
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Cancer 2018 10.7150/jca.26068 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST
    View PubMed
  • NAT GENET 2018 10.1038/s41588-018-0138-4 A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors Alvarez1, MJ; Subramaniam, PS; Tang, LH; Grunn, A; Aburi, M; Rieckhof, G; Komissarova, EV; Hagan, EA; Bodei, L; Clemons, PA; Dela Cruz, FS; Dhall, D; Diolaiti, D; Fraker, DA; Ghavami, A; Kaemmerer, D; Karan, C; Kidd, M; Kim, KM; Kim, HC; Kunju, LP; Langel, U; Li, Z; Lee, J; Li, H; LiVolsi, V; Pfragner, R; Rainey, AR; Realubit, RB; Remotti, H; Regberg, J; Roses, R; Rustgi, A; Sepulveda, AR; Serra, S; Shi, CJ; Yuan, XP; Barberis, M; Bergamaschi, R; Chinnaiyan, AM; Detre, T; Ezzat, S; Frilling, A; Hommann, M; Jaeger, D; Kim, MK; Knudsen, BS; Kung, AL; Leahy, E; Metz, DC; Milsom, JW; Park, YS; Reidy-Lagunes, D; Schreiber, S; Washington, K; Wiedenmann, B; Modlin, I; Califano, A
    View PubMed
  • J Cancer 2018 10.7150/jca.24948 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
    View PubMed
  • LANCET ONCOL 2018 10.1016/S1470-2045(18)30140-2 Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial Xu1, RH; Muro, K; Morita, S; Iwasa, S; Han, SW; Wang, W; Kotaka, M; Nakamura, M; Ahn, JB; Deng, YH; Kato, T; Cho, SH; Ba, Y; Matsuoka, H; Lee, KW; Zhang, T; Yamada, Y; Sakamoto, J; Park, YS; Kim, TW
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • J Cancer 2018 10.7150/jca.25132 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY
    View PubMed
  • MOL CANCER THER 2018 10.1158/1535-7163.MCT-17-0535 MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis Kim1, HK; Lee, I; Bang, H; Kim, HC; Lee, WY; Yun, SH; Lee, J; Lee, SJ; Park, YS; Kim, KM; Kang, WK
    View PubMed
  • J CLIN ONCOL 2018 10.1200/JCO.2017.74.3245 Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study Xu1, JM; Kim, TW; Shen, L; Sriuranpong, V; Pan, HM; Xu, RH; Guo, WJ; Han, SW; Liu, TS; Park, YS; Shi, CM; Bai, YX; Bi, F; Ahn, JB; Qin, SK; Li, Q; Wu, CP; Ma, D; Lin, DH; Li, J
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2016.535 Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study Choi1, Y; Yun, MS; Lim, SH; Lee, J; Ahn, JH; Kim, YJ; Park, KH; Park, YS; Lim, HY; An, H; Suh, DC; Kim, YH
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22511 Elevated CEA is associated with worse survival in recurrent rectal cancer Cho1, WK; Choi, DH; Park, HC; Park, W; Yu, JI; Park, YS; Park, JO; Lim, HY; Kang, WK; Kim, HC; Cho, YB; Yun, SH; Lee, WY
    View PubMed
  • INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22394 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.3750 MerTK is a novel therapeutic target in gastric cancer Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18168 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.20492 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • J Cancer 2017 10.7150/jca.19458 The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST
    View PubMed
  • J Cancer 2017 10.7150/jca.18286 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3351-4 A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo Ueno1, M; Li, CP; Ikeda, M; Ishii, H; Mizuno, N; Yamaguchi, T; Ioka, T; Oh, DY; Ichikawa, W; Okusaka, T; Matsuyama, Y; Arai, D; Chen, LT; Park, YS; Furuse, J
    View PubMed
  • TARGET ONCOL 2017 10.1007/s11523-017-0502-9 A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer Michael1, M; Bang, YJ; Park, YS; Kang, YK; Kim, TM; Hamid, O; Thornton, D; Tate, SC; Raddad, E; Tie, J
    View PubMed
  • EUR RADIOL 2017 10.1007/s00330-016-4644-4 Disappearing or residual tiny (ae<currency>5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required? Kim1, SS; Song, KD; Kim, YK; Kim, HC; Huh, JW; Park, YS; Park, JO; Kim, ST
    View PubMed
  • J Cancer 2017 10.7150/jca.19582 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • TUMORI 2017 10.5301/tj.5000666 Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer Yu1, JI; Park, HC; Lim, DH; Park, JO; Park, YS; Kim, ST; Choi, SH; Choi, DW; Han, IW; Heo, JS
    View PubMed
  • Oncologist. 2017 Mar;22(3):293-303. doi: 10.1634/theoncologist.2016-0166. Epub 2017 Feb 16. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer Kim JW11, Lee KW1, Kim KP2, Lee JH1, Hong YS2, Kim JE2, Kim SY2,3, Park SR2,3, Nam BH3, Cho SH4, Chung IJ4, Park YS5, Oh HS6, Lee MA7, Kang HJ8, Park YI3, Song EK9, Han HS10, Lee KT11, Shin DB12, Kang JH13, Zang DY14, Kim JH15, Kim TW16.
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial Sclafani F11, Kim TY2, Cunningham D1, Kim TW3, Tabernero J4, Schmoll HJ5, Roh JK6, Kim SY7, Park YS8, Guren TK9, Hawkes E1, Clarke SJ10, Ferry D11, Frodin JE12, Ayers M13, Nebozhyn M13, Peckitt C1, Loboda A13, Watkins DJ1.
    View PubMed
  • Chin J Cancer. 2016 Dec 22;35(1):102. doi: 10.1186/s40880-016-0166-3. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab Kotaka M11, Xu R2, Muro K3, Park YS4, Morita S5, Iwasa S6, Uetake H7, Nishina T8, Nozawa H9, Matsumoto H10, Yamazaki K11, Han SW12, Wang W13, Ahn JB14, Deng Y15, Cho SH16, Ba Y17, Lee KW18, Zhang T19, Satoh T20, Buyse ME21, Ryoo BY22, Shen L23, Sakamoto J24, Kim TW25.
    View PubMed
  • J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
    View PubMed
  • Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy Yu JI11, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.
    View PubMed
  • Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.
    View PubMed
  • Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1377-85. doi: 10.1007/s00432-016-2148-x. Epub 2016 Mar 24. Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer Oh BY11, Park YA1, Huh JW1, Cho YB1, Yun SH1, Lee WY1, Park HC2, Choi DH2, Park YS3, Kim HC4.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing Yoo KH11, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • Medicine (Baltimore). 2016 May;95(19):e3534. doi: 10.1097/MD.0000000000003534. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution Kim ST11, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
    View PubMed
  • Radiother Oncol. 2016 Feb;118(2):369-74. doi: 10.1016/j.radonc.2015.11.029. Epub 2015 Dec 17. A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis Kim KH11, Shin SJ2, Cho MS3, Ahn JB2, Jung M2, Kim TI4, Park YS5, Kim H6, Kim NK7, Koom WS8.
    View PubMed
  • BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors Park C11, Ha SY1, Kim ST2, Kim HC3, Heo JS3, Park YS2, Lauwers G4, Lee J2, Kim KM1.
    View PubMed
  • Medicine (Baltimore). 2016 Jan;95(3):e2582. doi: 10.1097/MD.0000000000002582. Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation Huh JW11, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, Lee WY, Park HC, Choi DH, Park JO, Park YS, Chun HK.
    View PubMed
  • Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7. Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery Kim TG11, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
    View PubMed
  • Support Care Cancer. 2016 Jan;24(1):301-9. doi: 10.1007/s00520-015-2783-9. Epub 2015 Jun 4. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects Hwang IG11, Kang JH2, Oh SY3,4, Lee S5, Kim SH5, Song KH6, Son C7, Park MJ8, Kang MH2, Kim HG2, Lee J9, Park YS9, Sun JM9, Kim HJ10, Kim CK10, Yi SY11, Jang JS1, Park K12,13, Kim HJ5.
    View PubMed
  • Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1015-22. doi: 10.1016/j.ijrobp.2015.08.037. Epub 2015 Aug 28. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer Jung M11, Shin SJ1, Koom WS2, Jung I3, Keum KC2, Hur H4, Min BS4, Baik SH4, Kim NK4, Kim H5, Lim JS6, Hong SP7, Kim TI7, Roh JK1, Park YS8, Ahn JB9.
    View PubMed
  • J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer Sclafani F11, Kim TY1, Cunningham D2, Kim TW1, Tabernero J1, Schmoll HJ1, Roh JK1, Kim SY1, Park YS1, Guren TK1, Hawkes E1, Clarke SJ1, Ferry D1, Frodin JE1, Ayers M1, Nebozhyn M1, Peckitt C1, Loboda A1, Mauro DJ1, Watkins DJ1.
    View PubMed
  • Asia Pac J Clin Oncol. 2015 Dec;11(4):334-42. doi: 10.1111/ajco.12409. Epub 2015 Oct 15. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry Park YS11, Ji J2, Zalcberg JR3, El-Serafi M4, Buzaid A5, Ghosn M6.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):738-46. doi: 10.4143/crt.2014.224. Epub 2015 Feb 16. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopatholoqical Analysis of 72 Cases in a Single Institute Shin Y11, Ha SY1, Hyeon J1, Lee B1, Lee J2, Jang KT1, Kim KM1, Park YS2, Park CK1.
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):790-5. doi: 10.4143/crt.2014.126. Epub 2014 Dec 2. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer Kim ST11, Kim TW2, Kim KP2, Kim TY3, Han SW3, Lee JY1, Lim SH1, Lee MY1, Kim H1, Park YS1.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24320-32. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
    View PubMed
  • Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients Kim JE11, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW.
    View PubMed
  • Oncology. 2015;89(1):14-22. doi: 10.1159/000371390. Epub 2015 Mar 11. Is Chemoradiotherapy Beneficial for Stage IV Rectal Cancer Huh JW11, Kim HC, Park HC, Choi DH, Park JO, Park YS, Park YA, Cho YB, Yun SH, Lee WY, Chun HK.
    View PubMed
  • Ann Surg Oncol. 2015 Apr;22(4):1308-14. doi: 10.1245/s10434-014-4146-z. Epub 2014 Oct 16. Salvage Radiation Therapy for Isolated Local Recurrence of Extrahepatic Cholangiocarcinoma After Radical Surgery: A Retrospective Study Kim SW11, Lim do H, Park HC, Park W, Park JO, Park YS.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Apr;75(4):757-62. doi: 10.1007/s00280-015-2691-1. Epub 2015 Feb 13. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer Hwang IG11, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC.
    View PubMed
  • J Surg Oncol. 2015 Mar 15;111(4):439-44. doi: 10.1002/jso.23835. Epub 2014 Dec 9. Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Curative Resection for Rectal Cancer: Is it Necessary for all Patients Jung KU11, Kim HC, Park JO, Park YS, Park HC, Choi DH, Cho YB, Yun SH, Lee WY, Chun HK.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Yonsei Med J. 2015 Jan;56(1):82-8. doi: 10.3349/ymj.2015.56.1.82. Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis Huh JW11, Lee WY2, Kim SH3, Park YA1, Cho YB1, Yun SH1, Kim HC1, Park HC4, Choi DH4, Park JO5, Park YS5, Chun HK6.
    View PubMed
  • Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21. Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Jung HA11, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Korean J Intern Med. 2015 Jan;30(1):88-95. doi: 10.3904/kjim.2015.30.1.88. Epub 2014 Dec 30. The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain Kang JH11, Oh SY2, Song SY3, Lee HY3, Kim JH4, Lee KE5, Lee HR6, Hwang IG7, Park SH8, Kim WS8, Park YS8, Park K8.
    View PubMed
  • Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
    View PubMed
  • BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial Kim ST1, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS1.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • Anticancer Res. 2014 Nov;34(11):6585-91. Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study Lee SJ11, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim DH3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.
    View PubMed
  • Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial Hong YS11, Nam BH2, Kim KP1, Kim JE1, Park SJ1, Park YS3, Park JO3, Kim SY4, Kim TY5, Kim JH6, Ahn JB7, Lim SB8, Yu CS8, Kim JC8, Yun SH9, Kim JH10, Park JH10, Park HC11, Jung KH1, Kim TW12.
    View PubMed
  • Oncology. 2014;87(5):280-92. doi: 10.1159/000365593. Epub 2014 Aug 15. Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer Sohn BS11, Park SJ, Kim JE, Kim KP, Hong YS, Suh C, Kim YS, Kim SY, Im SA, Kim SY, Kim JH, Ahn JB, Park YS, Kim TW.
    View PubMed
  • Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26. Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus Cheng AL11, Li J2, Vaid AK3, Ma BB4, Teh C5, Ahn JB6, Bello M7, Charoentum C8, Chen LT9, de Lima Lopes G Jr10, Ho GF11, Kong HL12, Lam KO13, Liu TS14, Park YS15, Sriuranpong V16, Sudoyo AW17, Wang JY18, Zhang J19, Zhang SZ20, Ciardiello F21, K?hne CH22, Shaw M23, Kim TW24.
    View PubMed
  • Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66. Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer Kim ST11, Sohn I2, DO IG3, Jang J4, Kim SH3, Jung IH5, Park JO1, Park YS1, Talasaz A6, Lee J1, Kim HC7.
    View PubMed
  • PLoS One. 2014 Aug 4;9(8):e103551. doi: 10.1371/journal.pone.0103551. eCollection 2014. Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status Lee J11, Jain A2, Kim P2, Lee T2, Kuller A2, Princen F2, In-GuDo3, Kim SH3, Park JO1, Park YS1, Singh S2, Kim HC4.
    View PubMed
  • Colorectal Dis. 2014 Aug;16(8):O257-63. doi: 10.1111/codi.12554. The adequacy of the distal resection margin after preoperative chemoradiotherapy for rectal cancer Kim TG11, Park W, Choi DH, Kim SH, Kim HC, Lee WY, Park JO, Park YS.
    View PubMed
  • Med Oncol. 2014 Jul;31(7):23. doi: 10.1007/s12032-014-0023-7. Epub 2014 Jun 10. Prognostic and predictive value of metabolic tumor volume on F-18-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib Choi MK111, Choi JY, Lee J, Heo JS, Choi SH, Choi DW, Lee KT, Lee JK, Lee KH, Park JO, Park YS, Lim HY.
    View PubMed
  • Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Lee J11, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.
    View PubMed
  • Invest New Drugs. 2014 Apr;32(2):369-76. doi: 10.1007/s10637-013-0059-0. Epub 2014 Jan 16. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis Jo JC11, Hong YS, Kim KP, Lee JL, Lee J, Park YS, Kim SY, Ryu JS, Lee JS, Kim TW.
    View PubMed
  • PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014. Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery Lee J11, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim DH6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.
    View PubMed
  • Am J Clin Oncol. 2014 Feb;37(1):19-23. doi: 10.1097/COC.0b013e31826b9c94. A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group Hong YS11, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, Ahn JB, Jung KH, Im SA, Kim TY, Kim JH, Park YS, Kim TW.
    View PubMed
  • Int J Colorectal Dis. 2014 Feb;29(2):193-200. doi: 10.1007/s00384-013-1797-3. Epub 2013 Dec 10. Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients Kim TG11, Park W, Choi DH, Park HC, Kim SH, Cho YB, Yun SH, Kim HC, Lee WY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Chun HK.
    View PubMed
  • Radiother Oncol. 2014 Jan;110(1):150-4. doi: 10.1016/j.radonc.2013.11.013. Epub 2014 Jan 7. Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02) Lee JH11, Kim JG2, Oh ST2, Lee MA3, Chun HG3, Kim DY4, Kim TH4, Kim SY4, Baek JY4, Park JW4, Oh JH4, Park HC5, Choi DH5, Park YS6, Kim HC7, Chie EK8, Jang HS9.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Hong JY11, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.
    View PubMed
  • Am J Clin Oncol. 2013 Dec;36(6):565-71. doi: 10.1097/COC.0b013e31825d52d5. Randomized Phase II Study of Capecitabine With or Without Oxaliplatin as First-line Treatment for Elderly or Fragile Patients With Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group CO06-01 Hong YS11, Jung KH, Kim HJ, Kim KP, Kim SY, Lee JL, Shim BY, Zang DY, Kim JH, Ahn JB, Park YS, Kim TW.
    View PubMed
  • Br J Cancer. 2013 Sep 17;109(6):1414-9. doi: 10.1038/bjc.2013.470. Epub 2013 Aug 29. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours Ahn HK11, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS.
    View PubMed
  • Cancer Chemother Pharmacol. 2013 Jul;72(1):223-30. doi: 10.1007/s00280-013-2190-1. Epub 2013 May 21. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis Ji JH11, Park SH, Lee J, Kim TW, Hong YS, Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, Shim BY, Park YS.
    View PubMed
  • Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51. doi: 10.1007/s00280-013-2075-3. Epub 2013 Jan 13. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer Lee KH11, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY.
    View PubMed
  • Cancer Sci. 2013 Jan;104(1):111-5. doi: 10.1111/cas.12041. Epub 2012 Nov 26. Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer Lee EM11, Hong YS, Kim KP, Lee JL, Kim SY, Park YS, Choi DH, Kim JH, Lim SB, Yu CS, Kim JC, Lee JH, Kim AY, Kim TW.
    View PubMed
  • BMC?Cancer.?2012 Dec 12;12:594. doi: 10.1186/1471-2407-12-594. Unique perception of clinical trials by Korean cancer patients Lee SJ11,?Park LC,?Lee J,?Kim S,?Choi MK,?Hong JY,?Park S,?Maeng CH,?Chang W,?Kim YS,?Park SH,?Park JO,?Lim HY,?Kang WK,?Park YS.
    View PubMed
  • Cancer. 2012 Dec 15;118(24):6162-70. doi: 10.1002/cncr.27675. Epub 2012 Jun 26. Phase 2 Study of Everolimus Monotherapy in Patients With Nonfunctioning Neuroendocrine Tumors or Pheochromocytomas/Paragangliomas Oh DY11, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ.
    View PubMed
  • Lancet Oncol. 2012 Nov;13(11):1125-32. doi: 10.1016/S1470-2045(12)70363-7. Epub 2012 Oct 10. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial Hong YS11, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW.
    View PubMed
  • Invest New Drugs. 2012 Jun;30(3):1164-74. doi: 10.1007/s10637-011-9651-3. Epub 2011 Mar 15. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research Oh DY11, Lee KW, Lee KH, Sohn CH, Park YS, Zang DY, Ryoo HM, Song HS, Kim JS, Kang HJ, Kim BS, Bang YJ.
    View PubMed
  • Clinical and Cost Effectiveness of Bevacizumab plus FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
  • PLoS One.?2012;7(4):e34456. doi: 10.1371/journal.pone.0034456. Epub 2012 Apr 2. Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene Lee J11,?Sung CO,?Lee EJ,?Do IG,?Kim HC,?Yoon SH,?Lee WY,?Chun HK,?Kim KM,?Park YS.
    View PubMed
  • Cancer Chemother Pharmacol. 2012 Jan;69(1):91-7. doi: 10.1007/s00280-011-1668-y. Epub 2011 May 24. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial Kim SH11, Shin SJ, Kim SY, Lee SH, Park YS, Park SH, Lee KH, Kim TW, Hong YS, Ahn JB.
    View PubMed
  • Invest New Drugs. 2011 Oct;29(5):1073-80. doi: 10.1007/s10637-010-9418-2. Epub 2010 Mar 21. Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer Shin SJ11, Jeong JH, Park YS, Lee KH, Shim BY, Kim TW, Oh do Y, Lee MA, Kim YT, Kim YH, Zang DY, Roh JK, Ahn JB.
    View PubMed
  • Asia Pac J Clin Oncol. 2011 Sep;7(3):293-9. doi: 10.1111/j.1743-7563.2011.01423.x. Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea Lim T11, Lee J, Kim JJ, Lee JK, Lee KT, Kim YH, Kim KW, Kim S, Sohn TS, Choi DW, Choi SH, Chun HK, Lee WY, Kim KM, Jang KT, Park YS.
    View PubMed
  • Invest New Drugs. 2011 Apr;29(2):366-73. doi: 10.1007/s10637-009-9363-0. Epub 2009 Dec 9. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer Kim C11, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK.
    View PubMed
  • Lancet Oncol. 2011 Mar;12(3):256-62. doi: 10.1016/S1470-2045(11)70004-3. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study Kindler HL11, Ioka T, Richel DJ, Bennouna J, L?tourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E.
    View PubMed
  • Cancer Chemother Pharmacol. 2011 Jan;67(1):5-11. doi: 10.1007/s00280-010-1272-6. Epub 2010 Mar 6. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding Choi MK11, Ahn BJ, Yim DS, Park YS, Kim S, Sohn TS, Noh JH, Heo JS, Lee J, Park SH, Park JO, Lim HY, Kang WK.
    View PubMed
  • Med Oncol. 2010 Dec;27(4):1277-85. doi: 10.1007/s12032-009-9374-x. Epub 2009 Dec 1. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer Kim ST11, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK, Lee WY, Park YS.
    View PubMed
  • Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration Ahn BJ11, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.
    View PubMed
  • Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67. doi: 10.1007/s00280-009-1206-3. Epub 2009 Dec 24. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy Kim ST11, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    View PubMed
  • Cancer Chemother Pharmacol. 2010 Jul;66(2):229-35. doi: 10.1007/s00280-009-1150-2. Epub 2009 Oct 10. Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis Lee SJ11, Lee J, Lim HY, Kang WK, Choi CH, Lee JW, Kim TJ, Kim BG, Bae DS, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    View PubMed
  • BMC Cancer. 2010 Jan 29;10:25. doi: 10.1186/1471-2407-10-25. Metastatic lymph node in gastric cancer; Is it a real distant metastasis Lim do H11, Kim HS, Park YS, Lee J, Park SH, Lim HY, Ji SH, Park MJ, Yi SY, An JY, Sohn TS, Noh JH, Bae JM, Kim S, Park CK, Kang WK.
    View PubMed
  • Int J Colorectal Dis. 2009 Nov;24(11):1311-6. doi: 10.1007/s00384-009-0758-3. Epub 2009 Jul 17. A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer Kim HS11, Park MJ, Uhm JE, Lee Y, Lee HY, Kang EM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS.
    View PubMed
  • World J Gastroenterol. 2009 Oct 28;15(40):5086-90. Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases Oh SY11, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ.
    View PubMed
  • Cancer Chemother Pharmacol. 2009 Jul;64(2):347-53. doi: 10.1007/s00280-008-0878-4. Epub 2008 Dec 6. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer Kim KH11, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK.
    View PubMed
  • Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer Yi SY11, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK.
    View PubMed
  • Oncologist. 2009 May;14(5):540-7. doi: 10.1634/theoncologist.2008-0145. Epub 2009 May 2. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Kim TW11, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH, Kang WK, Shin DB, Bang YJ, Lee JS, Kang YK.
    View PubMed
  • Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor Ryu MH11, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    View PubMed
  • Yonsei Med J. 2007 Oct 31;48(5):827-32. Anal canal carcinoma: Experience from a single Korean institution Lee WS11, Chun HK, Lee WY, Yun SH, Yun H, Cho YB, Kang WK, Park YS, Huh SJ, Ahn YC, Park W.
    View PubMed
  • Cancer Chemother Pharmacol. 2007 Jan;59(1):17-21. Epub 2006 May 24. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer Park KW11, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.
    View PubMed
  • J Clin Oncol. 2007 Jan 1;25(1):102-9. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients Schmoll HJ11, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirz?n F, Haller DG.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • Hepatocellular carcinoma with metastasis to the breast
  • Cancer Chemother Pharmacol. 2005 Jul;56(1):10-4. Epub 2005 Mar 22. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study Lim DH11, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K.
    View PubMed
  • Jpn J Clin Oncol. 2005 Apr;35(4):214-7. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer Ji SH11, Park YS, Lee J, Lim DH, Park BB, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K.
    View PubMed
  • Tumour Biol. 2004 Jan-Apr;25(1-2):1-6. Expression of placental growth factor gene in lung cancer Woo IS11, Park MJ, Byun JH, Hong YS, Lee KS, Park YS, Lee JA, Park YI, Ahn HK.
    View PubMed